{"id":9185,"date":"2017-02-28T06:45:00","date_gmt":"2017-02-28T05:45:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/"},"modified":"2017-02-28T06:45:00","modified_gmt":"2017-02-28T05:45:00","slug":"forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","title":{"rendered":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier"},"content":{"rendered":"<p>[mfn_before_post]<\/p>\n<div class=\"mfn-preamble\"><strong><\/strong><\/div>\n<p><span><strong>28 februari 2017\u00a0 <em><\/em>\u00a0<\/strong><\/span><\/p>\n<p><span><strong>Handeln i aktierna i IRLAB Therapeutics AB (publ) inleds idag p\u00e5 Nasdaq First North Premier under kortnamnet \u201dIRLAB A\u201d med ISIN kod SE0009242225.<\/strong><\/span><\/p>\n<ul>\n<li><span>IRLAB har totalt 6 999 939 utest\u00e5ende aktier, varav 6\u00a0928 388 A-aktier f\u00f6rdelat p\u00e5 drygt 2\u00a0500 aktie\u00e4gare.<\/span><\/li>\n<li><span>Teckningskursen i den nyemission som f\u00f6ranledde listningen, och i vilken Bolaget erh\u00f6ll erforderligt antal aktie\u00e4gare f\u00f6r att uppfylla spridningskravet p\u00e5 Nasdaq First North Premier, uppgick till 60 kr per aktie, motsvarande en v\u00e4rdering av Bolaget om 420 mkr efter nyemission.<\/span><\/li>\n<li><span>Handeln av Bolagets aktier p\u00e5 Nasdaq First North Premier inleds idag, den 28 februari 2017, under kortnamnet \u201dIRLAB A\u201d med ISIN kod SE0009242225.<\/span><\/li>\n<\/ul>\n<p><span><strong>R\u00e5dgivare<\/strong><br \/>Stockholm Corporate Finance AB har varit finansiell r\u00e5dgivare och Advokatfirman Delphi i G\u00f6teborg KB legal r\u00e5dgivare till IRLAB i samband med nyemissionen. Aqurat Fondkommission AB agerade som emissionsinstitut och Avanza Bank AB som s\u00e4ljagent i samband med nyemissionen.<\/span><\/p>\n<p><span>FNCA Sweden AB \u00e4r Bolagets Certified Adviser p\u00e5 First North Premier.<\/span><\/p>\n<h3><span>F\u00f6r mer information:<\/span><\/h3>\n<table>\n<tbody>\n<tr>\n<td><span>Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/><\/span><\/td>\n<td><span>Viktor Siewertz, COO<\/span><\/td>\n<\/tr>\n<tr>\n<td><span>Tel: +46\u00a0730 75 77 01<\/span><\/td>\n<td><span>Tel: +46\u00a0727 10 70 70<\/span><\/td>\n<\/tr>\n<tr>\n<td><span>E-post: <a href=\"mailto:viktor.siewertz@irlab.se\" rel=\"nofollow\">nicholas.waters@irlab.se<\/a> \u00a0\u00a0\u00a0\u00a0 <\/span><\/td>\n<td><span>E-post: <a href=\"mailto:viktor.siewertz@irlab.se\" rel=\"nofollow\">viktor.siewertz@irlab.se<\/a><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span>Kort om IRLAB<\/span><span><br \/><\/span><\/strong><span>IRLAB bildades 2013 och grundar sin verksamhet p\u00e5 \u00f6ver 20 \u00e5rs forskning som startade redan p\u00e5 1990-talet, d\u00e5 under ledning av Nobelpristagare Professor Arvid Carlsson. IRLAB fokuserar fr\u00e4mst sin forskning p\u00e5 neurodegenerativa sjukdomar, i synnerhet substanser f\u00f6r medicinering vid Parkinsons sjukdom och demenser, f\u00f6r vilka det i dagsl\u00e4get finns ett behov av nya och f\u00f6rb\u00e4ttrade behandlingsmetoder.<\/span><\/p>\n<p><span>IRLAB har tv\u00e5 prim\u00e4ra l\u00e4kemedelskandidater, IRL752 och IRL790, b\u00e5da med genomf\u00f6rda Fas I-studier i friska frivilliga forskningspersoner, samt ytterligare tre projekt i preklinisk fas. IRLAB har ocks\u00e5 ett forskningsprogram som syftar till att ta fram l\u00e4kemedelskandidater med hj\u00e4lp av den unika och egenutvecklade forskningsplattformen, ISP.<\/span><\/p>\n<p><span>IRLAB \u00e4r baserat i G\u00f6teborg. IRLAB:s verksamhet bedrivs huvudsakligen genom dotterbolaget Integrative Research Laboratories Sweden AB.<\/span><\/p>\n<p><span>F\u00f6r mer information, v\u00e4nligen bes\u00f6k <a href=\"http:\/\/www.irlab.se\" rel=\"nofollow\">www.irlab.se<\/a><\/span><\/p>\n<p><span><strong><br \/><\/strong><\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span><strong><\/strong><\/span><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><span><strong><\/strong><\/span><\/p>\n<\/div>\n<p>[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[mfn_before_post] 28 februari 2017\u00a0 \u00a0 Handeln i aktierna i IRLAB Therapeutics AB (publ) inleds idag p\u00e5 Nasdaq First North Premier under kortnamnet \u201dIRLAB A\u201d med ISIN kod SE0009242225. IRLAB har totalt 6 999 939 utest\u00e5ende aktier, varav 6\u00a0928 388 A-aktier f\u00f6rdelat p\u00e5 drygt 2\u00a0500 aktie\u00e4gare. Teckningskursen i den nyemission som f\u00f6ranledde listningen, och i vilken [&hellip;]<\/p>\n","protected":false},"template":"","class_list":["post-9185","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-lhfi_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB\" \/>\n<meta property=\"og:description\" content=\"[mfn_before_post] 28 februari 2017\u00a0 \u00a0 Handeln i aktierna i IRLAB Therapeutics AB (publ) inleds idag p\u00e5 Nasdaq First North Premier under kortnamnet \u201dIRLAB A\u201d med ISIN kod SE0009242225. IRLAB har totalt 6 999 939 utest\u00e5ende aktier, varav 6\u00a0928 388 A-aktier f\u00f6rdelat p\u00e5 drygt 2\u00a0500 aktie\u00e4gare. Teckningskursen i den nyemission som f\u00f6ranledde listningen, och i vilken [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\",\"name\":\"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2017-02-28T05:45:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","og_locale":"sv_SE","og_type":"article","og_title":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB","og_description":"[mfn_before_post] 28 februari 2017\u00a0 \u00a0 Handeln i aktierna i IRLAB Therapeutics AB (publ) inleds idag p\u00e5 Nasdaq First North Premier under kortnamnet \u201dIRLAB A\u201d med ISIN kod SE0009242225. IRLAB har totalt 6 999 939 utest\u00e5ende aktier, varav 6\u00a0928 388 A-aktier f\u00f6rdelat p\u00e5 drygt 2\u00a0500 aktie\u00e4gare. Teckningskursen i den nyemission som f\u00f6ranledde listningen, och i vilken [&hellip;]","og_url":"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","url":"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","name":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2017-02-28T05:45:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}